J.W. Cole Advisors Inc. Purchases 174 Shares of Moderna, Inc. (NASDAQ:MRNA)

J.W. Cole Advisors Inc. boosted its position in Moderna, Inc. (NASDAQ:MRNA) by 8.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,222 shares of the company’s stock after purchasing an additional 174 shares during the quarter. J.W. Cole Advisors Inc.’s holdings in Moderna were worth $221,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. First Pacific Financial acquired a new position in Moderna in the 3rd quarter valued at $27,000. Arlington Trust Co LLC raised its holdings in shares of Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC raised its holdings in shares of Moderna by 54.1% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock worth $53,000 after buying an additional 180 shares in the last quarter. Archer Investment Corp raised its holdings in shares of Moderna by 71.2% during the 3rd quarter. Archer Investment Corp now owns 534 shares of the company’s stock worth $55,000 after buying an additional 222 shares in the last quarter. Finally, Parkside Financial Bank & Trust raised its holdings in shares of Moderna by 44.9% during the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock worth $58,000 after buying an additional 175 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Moderna Stock Performance

Shares of Moderna stock opened at $106.18 on Friday. Moderna, Inc. has a one year low of $62.55 and a one year high of $142.79. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The stock’s 50-day moving average is $102.15 and its 200 day moving average is $93.73.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company’s quarterly revenue was down 44.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.61 earnings per share. As a group, equities analysts anticipate that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on MRNA shares. Jefferies Financial Group reissued a “buy” rating and set a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price for the company in a report on Tuesday, January 2nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 target price on shares of Moderna in a report on Thursday, March 28th. Canaccord Genuity Group upped their target price on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a report on Friday, February 23rd. Finally, HSBC reaffirmed a “reduce” rating and issued a $86.00 target price (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $126.49.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 544 shares of the stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $99.05, for a total value of $53,883.20. Following the completion of the sale, the insider now directly owns 9,267 shares of the company’s stock, valued at $917,896.35. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CFO James M. Mock sold 647 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at $406,651. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Shannon Thyme Klinger sold 544 shares of the stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $99.05, for a total value of $53,883.20. Following the sale, the insider now directly owns 9,267 shares of the company’s stock, valued at $917,896.35. The disclosure for this sale can be found here. Insiders sold a total of 109,954 shares of company stock valued at $11,533,976 over the last ninety days. 15.70% of the stock is currently owned by insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.